PSY49 PATIENTS PREFERENCES IN OVERWEIGHT AND OBESITY THERAPY WITH DISCRETE CHOICE EXPERIMENTS  by Mühlbacher, AC & Bethge, S
13th Euro Abstracts A469
PSY47
VARIATION IN PRIMARY CARE CONSULTATION COSTS AMONG 
NON-CANCER PATIENTS TREATED WITH CHRONIC OPIOID 
ANALGESIA IN THE UNITED KINGDOM
Poole CD1, Conway P2, Baxter G2, Currie CJ3
1Pharmatelligence, Cardiff, UK; 2Grunenthal Ltd., Stokenchurch, UK; 3Cardiff University, 
Cardiff, Wales, UK
OBJECTIVES: Chronic pain affects around ﬁ ve million people in the UK. Non-
injectable, strong opioid analgesia is increasingly being used to manage chronic pain 
but this requires careful management to avoid common adverse effects. This study 
aimed to characterise variation in primary care consultation costs as a function of 
analgesic stability among patients treated with long-term, non-injectable opioids. 
METHODS: Cases with at least 6-months’ observation prior to opioid analgesia and 
no history of cancer were extracted from The Health Improvement Network database 
(THIN), a source of anonymised patient-level data from UK general practice. The 
number of different, strong opioid drugs (British Pain Society deﬁ ned) prescribed to 
each patient during their ﬁ rst year of chronic opioid analgesia was used a proxy 
measure of analgesia stability. Primary care consultations were costed using a standard 
tariff at £UK2007. RESULTS: A total of 21,261 cases were studied, of which 54% 
were female and the mean age at initiation of opioid analgesia was 62 years (sd 11). 
Prior to initiating strong opioid analgesia the annual, average, total cost of consulta-
tions with primary care health practitioners was £188 (95%CI £184 to £191). After 
initiation of opioid analgesia, patients treated with a single drug incurred annual 
consultation costs of £546 (£537 to £554) per year on average, and these costs 
increased sharply with each additional opioid: £706 (£686 to £726), £836 (£789 to 
£884), and £975 (£818 to £1132; pANOVA < 0.001) for two, three, and four or more 
opioids, respectively. The majority of consultations (84%) were with general practi-
tioners in the surgery. CONCLUSIONS: The occurrence of persistent pain was associ-
ated with a considerable increase in the rate and the related ﬁ nancial cost of 
consultations with health professionals in primary care. Furthermore, a substantial 
cost gradient was evident among patients who failed to be managed with stable opioid 
monotherapy during their ﬁ rst year of opioid analgesia.
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RESOURCE USE AND COSTS OF THE GASTRIC BYPASS SURGERY 
VERSUS CLINICAL TREATMENT FOR OBESE PATIENTS WITH 
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OBJECTIVES: To assess use of resources and costs of the surgical versus clinical 
treatment for obese patients with comorbidities, under the Brazilian private health 
care system. METHODS: In order to estimate the differences of resource use and costs 
related to surgery versus clinical treatment one panel of specialists was conducted to 
raise up the resources necessaries for the treatment from pre-operatory evaluation to 
the last medical visit after 5 years. For the clinical treatment group we assumed a 
conservative scenario where the complications are not considered. a micro costing 
technique based on public price lists was applied to value the resources from the panel 
considering only direct medical costs. a discount rate of 5% was assumed. RESULTS: 
For the ﬁ rst year the total costs per patient for the surgically treated group were 
R$14,547, for the open approach and R$31,415 for the laparoscopic approach (pre-
operatory assessment R$2,009, inpatient costs R$2,728 versus R$2,493, procedure 
R$7,233 versus R$24,478, complications R$323 versus R$181 and the clinical follow 
up R$2,254 for both) and for the clinical treated group the total costs per patient was 
R$7,545 where R$5,062 occurred due to the obesity management (diet, consults, and 
drugs for weight management) and R$2,488 for comorbidities (drugs, consults and 
exams for Diabetes TII, hypertension and hypercholesterolemia). After the ﬁ rst year 
the surgically treated group had R$1690 of annually costs for the follow up versus 
R$3290 for the clinical treatment group. After 5 years the total costs were R$22,284 
and R$39,153 for open and laparoscopic surgery and R$19,217 for the clinical treat-
ment. CONCLUSIONS: Findings suggest that gastric bypass can reduce the use of 
resources and costs related to the management of obese patients, under the Brazilian 
private health care system. 
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OBJECTIVES: Overweight is associated with increased risk of morbidity, mortality 
and appears to adversely affect health-related quality of life (HRQOL). Though 
advances in obesity therapy can be observed, the long-lasting outcome is dissatisfying. 
This study aims to investigate patients’ preferences of overweight and obesity therapy 
in the setting of rehabilitation. METHODS: Qualitative and quantitative methods 
were applied to identify key attributes. Literature review, focus groups (N = 44) and 
expert interviews (N = 5) were conducted to elicit relevant attributes and endpoints. 
a total of 64 possible therapy items were surveyed (N = 201) using a classic rating 
scale in 5-point Likert format. Psychometric tests (frequency, factor analysis, reliability 
tests) were used to verify the structure of relevant attributes. Discrete choice experi-
ments were developed using a fractional factorial design in fold over method. For 
statistical data analysis, we used a random effect logit models for the DCE. Finally a 
self-administered survey, measuring preferences, was conducted in Germany in 2009 
(n = 110). RESULTS: A total of 110 patients responded of which 51,82% were male, 
mean age 53,05 years, mean BMI 33,54 kg/m2 (SD 7,73) answered the questionnaire. 
The highest relevance for the respondents’ selection was the aspect of care coordina-
tion (Item 6: Coefﬁ cient 1.473; SE 0.185) and individual therapy (Item 4: Coefﬁ cient 
1.446; SE 0.188). The aspect of infrastructure of care was less relevant in the discrete 
choice experiment. All included attributes lead to signiﬁ cant coefﬁ cients. CONCLU-
SIONS: Weight reduction therapy should enable patients to receive a structured, 
coordinated and predeﬁ ned therapy that is individualized based on personal needs, 
behaviour and circumstances. Patients are willing to abandon infrastructural quality 
for getting better coordination, structure in there therapy. Further research is needed 
to distinguish the possible interpretations of the presented preference dimensions, the 
possibility of including them into weight loss programs and to take notice of hetero-
geneity within patient population in weight loss programs.
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OBJECTIVES: The study assessed whether, beyond general risks from obesity-related 
comorbidities, speciﬁ c comorbidity types were associated differentially with impair-
ments to health-related quality of life and work productivity. METHODS: Data were 
from the European 2008 National Health and Wellness Survey of German, Spanish, 
Italian, UK, and French adults. Logistic regressions identiﬁ ed signiﬁ cant predictors of 
presence vs. absence of obesity (BMI ≥ 30) among 62 medical conditions, for 52,206 
respondents with valid BMI data (of 53,524 total). Signiﬁ cant predictors were then 
submitted to a principal component analysis (PCA) to identify obesity-related compo-
nents accounting for the most variance. Conditions loading most highly on the result-
ing components were used to predict the following outcomes for all 10,391 obese 
respondents, using multiple regressions: physical (PCS) and mental (MCS) component 
summary scores from the SF-12v2 quality of life instrument, health utilities (SF-6D), 
and percentage overall work impairment (WPAI). Comparisons were against obese 
respondents with none of the PCA-identiﬁ ed conditions, controlling for the other 
conditions. RESULTS: Logistic regressions identiﬁ ed 35 obesity predictors that 
reduced to 9 PCA components with one condition loading prominently on each: 
hypertension, high cholesterol, arthritis, angina, thyroid condition, diabetes, chronic 
bronchitis, psoriasis, and urinary incontinence. All conditions except psoriasis pre-
dicted PCS reductions ranging from 1.22 (with presence of angina) to 9.02 (arthritis), 
ps < 0.001. All except diabetes and angina, and arthritis and hypertension (associated 
with MCS increases), predicted MCS reductions ranging from 0.70 (cholesterol) to 
4.11 (incontinence), ps < 0.05. All except angina predicted health utilities reductions 
ranging from 0.011 (hypertension) to 0.077 (incontinence), ps < 0.001. Among 5,242 
employed respondents, all except angina and psoriasis predicted overall work impair-
ments of 2.11% (hypertension) to 12.48% (bronchitis), ps < 0.05. CONCLUSIONS: 
Obese EU respondents differed signiﬁ cantly in quality of life and productivity impair-
ments, based on both presence and speciﬁ c types of comorbidities. These ﬁ ndings can 
help guide interventions among obesity-related conditions.
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OBJECTIVES: Treating chronic pain involves difﬁ cult trade-offs between the goals of 
pain relief and avoidance of side-effects, but evidence is scarce on relative perspectives 
of physicians and pain sufferers. We studied each group’s preferences concerning 
classical strong opioids in France, Germany, Italy, Spain, Sweden and the UK. 
METHODS: In online, discrete choice experiments (DCE), chronic pain sufferers (n 
= 242) and physicians (n = 270) chose between hypothetical proﬁ les or an opt-out in 
15 choice tasks. Proﬁ le descriptions were based on attributes elicited in focus groups 
with 84 sufferers and semi-structured interviews with 11 physicians. Models were 
speciﬁ ed by multinomial logit and individual respondent part-worths were estimated 
by hierarchical Bayesian regression. RESULTS: All main-effects, but no interactions, 
were signiﬁ cant. Sufferers ranked nausea, pain impact, energy, alertness and constipa-
tion; and physicians ranked pain response, CNS effects, nausea, dosage form and 
constipation in descending order of importance. Sufferers were unwilling to incur 
severe side-effects to relieve pain, opting out in approximately half of the choice tasks, 
while physicians were always willing to trade between proﬁ les. The models predicted 
physicians’ choices well but those of pain sufferers less so. No age, sex or country 
effects were seen but stronger preferences were expressed by the minority (15%) of 
physicians treating non-cancer pain, and by the 55% of sufferers who had ever dis-
continued chronic pain medication and the 41% who reported extreme pain and 
